EP0488401A1 - Une préparation pharmaceutique à libération contrôlée pour l'implantation intraoculaire - Google Patents
Une préparation pharmaceutique à libération contrôlée pour l'implantation intraoculaire Download PDFInfo
- Publication number
- EP0488401A1 EP0488401A1 EP91120586A EP91120586A EP0488401A1 EP 0488401 A1 EP0488401 A1 EP 0488401A1 EP 91120586 A EP91120586 A EP 91120586A EP 91120586 A EP91120586 A EP 91120586A EP 0488401 A1 EP0488401 A1 EP 0488401A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- intra
- controlled
- pharmaceutical preparation
- polylactic acid
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
- A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A61K9/204—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/902—Method of implanting
- Y10S623/905—Eye
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP338853/90 | 1990-11-30 | ||
| JP33885390 | 1990-11-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP0488401A1 true EP0488401A1 (fr) | 1992-06-03 |
Family
ID=18322023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP91120586A Withdrawn EP0488401A1 (fr) | 1990-11-30 | 1991-11-29 | Une préparation pharmaceutique à libération contrôlée pour l'implantation intraoculaire |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US5501856A (fr) |
| EP (1) | EP0488401A1 (fr) |
| JP (1) | JP3116489B2 (fr) |
| KR (1) | KR0185215B1 (fr) |
| CA (1) | CA2056513A1 (fr) |
Cited By (105)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0654256A4 (fr) * | 1993-02-26 | 1995-01-04 | Santen Pharmaceutical Co Ltd | Bouchon de sclerotique biodegradable. |
| WO1996013286A3 (fr) * | 1994-10-26 | 1996-06-20 | Houston Biotechnology | Procedes et compositions de modulation de la proliferation cellulaire et de la cicatrisation |
| WO1997028833A1 (fr) * | 1996-02-12 | 1997-08-14 | Houston Biotechnology Incorporated | Procedes et compositions de modulation de la proliferation cellulaire et de cicatrisation de lesions |
| US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| EP0992244A4 (fr) * | 1997-07-02 | 2001-01-17 | Santen Pharmaceutical Co Ltd | Bouchons scleraux d'acide polylactique |
| WO2002002076A3 (fr) * | 2000-07-05 | 2002-07-04 | Oculex Pharm Inc | Procedes servant a traiter des etats inflammatoires de l'oeil |
| WO2002078713A1 (fr) * | 2001-03-28 | 2002-10-10 | Santen Pharmaceutical Co., Ltd. | Medicaments contre les affections retiniennes et choroidiennes contenant des steroides comme principe actif |
| US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| WO2004062649A3 (fr) * | 2003-01-09 | 2004-11-04 | Allergan Inc | Implant oculaire biodegradable |
| EP1550471A1 (fr) * | 2000-11-29 | 2005-07-06 | Allergan Inc. | Implants intra-oculaires pour la prévention du rejet de greffe dans l'oeil |
| WO2005110366A1 (fr) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Derive d'estradiol, derive d'estratopone contenant un implant intra-oculaire a liberation prolongee et leurs procedes de fabrication |
| WO2005110380A1 (fr) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Implants intraoculaires a liberation soutenue contenant un antagoniste du recepteur beta-adrenergique et methodes de traitement de neuropathies oculaires |
| WO2006017347A2 (fr) | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Compositions ophtalmiques et procédés de traitement de conditions ophtalmiques |
| EP1637164A2 (fr) * | 1995-06-02 | 2006-03-22 | Allergan, Inc. | Amélioration apportée à une formulation destinée à la libération contrôlée des médicaments par combinaison d'agents hydrophiles et hydrophobes |
| WO2008020087A1 (fr) | 2006-08-08 | 2008-02-21 | Fundacion Inasmet | Système optique implantable, son procédé de mise au point et ses applications |
| EP1637126A3 (fr) * | 2000-07-05 | 2009-10-21 | Allergan, Inc. | Méthodes de traitement des inflammations de l'oeil |
| WO2010054403A1 (fr) | 2008-11-10 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Procédés et compositions pour le traitement de troubles associés au complément |
| EP2218424A1 (fr) | 2006-12-01 | 2010-08-18 | Allergan, Inc. | Dispositif pour l'administration intraoculaire d'un médicament |
| WO2010151526A1 (fr) | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Anticorps bispécifiques se liant aux protéines du complément |
| EP2329811A1 (fr) | 2004-08-13 | 2011-06-08 | Allergan, Inc. | Implant oculaire fabriqué par un procédé d'extrusion multiple |
| WO2011103599A2 (fr) | 2010-02-19 | 2011-08-25 | The Regents Of The Universith Of California | Réactifs de liaison de la protéine membranaire épithéliale 2 (emp2) et leurs utilisations thérapeutiques dans des maladies oculaires |
| WO2011137395A1 (fr) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anticorps anti-c5a et méthodes pour utiliser les anticorps |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| WO2012106634A1 (fr) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Utilisation d'un anticorps anti-cd200 pour prolonger la survie d'allogreffes |
| US8580292B2 (en) | 2004-04-30 | 2013-11-12 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| EP2664347A1 (fr) | 2008-07-18 | 2013-11-20 | Allergan, Inc. | Procédé de traitement de la dégénérescence maculaire liée à l'âge atrophique |
| US8609613B2 (en) | 2003-12-05 | 2013-12-17 | Bristol-Myers Squibb Company | Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8728483B2 (en) | 2008-05-22 | 2014-05-20 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| EP2752427A1 (fr) | 2009-02-24 | 2014-07-09 | Alexion Pharmaceuticals, Inc. | Anticorps contenant des peptides mimétiques TPO/EPO thérapeutiques |
| US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8846094B2 (en) | 2003-11-12 | 2014-09-30 | Allergan, Inc. | Peripherally administered viscous formulations |
| WO2014160958A1 (fr) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire |
| US9011857B2 (en) | 2005-04-15 | 2015-04-21 | The Regents Of The University Of California | Methods of treating cancer by administering EMP2 antibodies |
| US9017655B2 (en) | 2008-11-24 | 2015-04-28 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
| US9079949B1 (en) | 2014-03-07 | 2015-07-14 | Alexion Pharmaceuticals, Inc. | Anti-C5 antibodies having improved pharmacokinetics |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US9110064B2 (en) | 2005-02-28 | 2015-08-18 | The Regents Of The University Of California | Methods for diagnosis and treatment of endometrial cancer |
| US9138480B2 (en) | 2009-11-09 | 2015-09-22 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| US9234028B2 (en) | 2008-02-14 | 2016-01-12 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| US9259488B2 (en) | 2012-08-17 | 2016-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Anti-C3d antibody conjugates and methods of detecting complement activation |
| US9265775B2 (en) | 2003-11-12 | 2016-02-23 | Allergan, Inc. | Pharmaceutical compositions |
| WO2016054522A1 (fr) | 2014-10-03 | 2016-04-07 | Ntercept, Llc | Compositions et procédés pour inhiber l'activité biologique de biomolécules solubles |
| WO2016123454A1 (fr) | 2015-01-29 | 2016-08-04 | Board Of Trustees Of Miching State University | Polypeptides cryptiques et leurs utilisations |
| AU2013221985B2 (en) * | 2004-07-12 | 2016-09-01 | Allergan, Inc. | Ophthalmic compositions and methods for treating ophthalmic conditions |
| US9464135B2 (en) | 2007-10-08 | 2016-10-11 | The Regents Of The University Of California | Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR) |
| US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| US9572859B2 (en) | 2004-01-20 | 2017-02-21 | Allergan, Inc. | Compositions and methods for localized therapy of the eye |
| US9610246B2 (en) | 2013-02-15 | 2017-04-04 | Allergan, Inc. | Sustained drug delivery implant |
| WO2017176762A1 (fr) | 2016-04-06 | 2017-10-12 | Nanotics, Llc | Particules comprenant des sous-particules ou des échafaudages d'acide nucléique |
| US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| EP3290922A1 (fr) | 2013-08-07 | 2018-03-07 | Alexion Pharmaceuticals, Inc. | Protéines de bio-marqueurs de syndrome hémolytique et urémique atypique |
| WO2018236904A1 (fr) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations |
| WO2019014328A2 (fr) | 2017-07-11 | 2019-01-17 | Compass Therapeutics Llc | Anticorps agonistes qui lient cd137 humain et leurs utilisations |
| WO2019023564A1 (fr) | 2017-07-27 | 2019-01-31 | Alexion Pharmaceutical, Inc. | Formules d'anticorps anti-c5 à haute concentration |
| WO2019036605A2 (fr) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | Agents de liaison à spécificité multiple de chimiokines cxc et leurs utilisations |
| US10221232B2 (en) | 2006-11-22 | 2019-03-05 | Bristol-Myers Squibb Company | Methods of treating cancer by administering IGF-IR binding molecules |
| WO2019051073A1 (fr) | 2017-09-08 | 2019-03-14 | Bristol-Myers Squibb Company | Facteur de croissance des fibroblastes 21 (fgf-21) modifié destiné à une utilisation dans des méthodes de traitement de la stéatohépatite non alcoolique (nash) |
| WO2019067499A1 (fr) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | Signature de biomarqueur pour la prédiction d'une réponse tumorale vis-à-vis d'une thérapie anti-cd200 |
| WO2019089753A2 (fr) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Anticorps cd137 et antagonistes pd-1 et leurs utilisations |
| WO2019100052A2 (fr) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Anticorps cd137 et anticorps ciblant un antigène tumoral et leurs utilisations |
| WO2019178269A2 (fr) | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Anticorps qui se lient à cd39 et leurs utilisations |
| WO2019200357A1 (fr) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarqueur pour agents thérapeutiques ciblant cd47 et leurs utilisations |
| WO2019204743A1 (fr) | 2018-04-19 | 2019-10-24 | Checkmate Pharmaceuticals, Inc. | Agonistes de récepteur de type rig-i synthétique |
| WO2019226658A1 (fr) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation |
| WO2019226617A1 (fr) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk |
| WO2020018715A1 (fr) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Protéines de fusion à base d'échafaudage d'immunoglobuline multimère soluble et leurs utilisations |
| WO2020033923A1 (fr) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Agents de liaison à l'antigène qui se lient à cd277 et leurs utilisations |
| WO2020033926A2 (fr) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Anticorps qui se lient à cd277 et leurs utilisations |
| WO2020033925A2 (fr) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Anticorps qui se lient à cd277 et leurs utilisations |
| US10627415B2 (en) | 2015-03-12 | 2020-04-21 | Board Of Trustees Of Michigan State University | Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease |
| WO2020097054A1 (fr) | 2018-11-06 | 2020-05-14 | Georgetown University | Traitement de la stéatohépatite non alcoolique avec des inhibiteurs de la cck |
| WO2020150496A1 (fr) | 2019-01-16 | 2020-07-23 | Compass Therapeutics Llc | Formulations d'anticorps qui se lient au cd137 humain et leurs utilisations |
| WO2020163782A2 (fr) | 2019-02-08 | 2020-08-13 | The Uab Research Foundation | Composition pour le traitement et la prévention de la maladie inflammatoire chronique de l'intestin |
| EP3736287A1 (fr) | 2015-05-11 | 2020-11-11 | The Johns Hopkins University | Anticorps auto-immuns destinés à être utilisés pour inhiber la croissance de cellules cancéreuses |
| WO2021062244A1 (fr) | 2019-09-25 | 2021-04-01 | Surface Oncology, Inc. | Anticorps anti-il-27 et leurs utilisations |
| WO2021067526A1 (fr) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Inhibiteurs du complément pour le traitement d'une réponse médiée par le complément induite par un médicament |
| WO2021080682A1 (fr) | 2019-10-24 | 2021-04-29 | Massachusetts Institute Of Technology | Anticorps monoclonaux qui se lient au cd161 humain et leurs utilisations |
| WO2021081353A1 (fr) | 2019-10-23 | 2021-04-29 | Checkmate Pharmaceuticals, Inc. | Agonistes de récepteur du type rig-i synthétiques |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| WO2021231720A1 (fr) | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Méthode d'utilisation de vésicules extracellulaires pour détecter une activation du complément, et leurs utilisations pour l'évaluation et/ou la surveillance du traitement d'une maladie à médiation par le complément |
| US11191851B2 (en) | 2012-08-17 | 2021-12-07 | Musc Foundation For Research Development | Anti-C3d antibody conjugates and methods of detecting complement activation |
| US11332524B2 (en) | 2018-03-22 | 2022-05-17 | Surface Oncology, Inc. | Anti-IL-27 antibodies and uses thereof |
| WO2022236134A1 (fr) | 2021-05-07 | 2022-11-10 | Surface Oncology, Inc. | Anticorps anti-il-27 et leurs utilisations |
| WO2022251446A1 (fr) | 2021-05-28 | 2022-12-01 | Alexion Pharmaceuticals, Inc. | Procédés de détection de biomarqueurs cm-tma |
| US11655303B2 (en) | 2019-09-16 | 2023-05-23 | Surface Oncology, Inc. | Anti-CD39 antibody compositions and methods |
| WO2023230128A1 (fr) | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Utilisation d'anticorps anti-il-27 |
| WO2023230116A1 (fr) | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Utilisation d'anticorps anti-il-27 |
| WO2024054436A1 (fr) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Profils de biomarqueurs de diagnostic et de pronostic chez des patients ayant une microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) |
| US12084509B2 (en) | 2020-04-30 | 2024-09-10 | Duke University | Gene signatures for monitoring acute rejection and methods of using same |
| US12128101B2 (en) | 2017-10-26 | 2024-10-29 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) |
| WO2024238422A1 (fr) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Utilisation d'un panel de lectines pour la détection de biomarqueurs du complément dans des vésicules extracellulaires d'urine |
| WO2024238421A1 (fr) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Utilisation de biomarqueurs pour l'identification et le traitement de troubles médiées par le complément |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| US12358978B2 (en) | 2018-12-13 | 2025-07-15 | Surface Oncology, LLC | Anti-IL-27 antibodies and uses thereof |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| US12459992B2 (en) | 2016-05-27 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| US12460012B2 (en) | 2018-06-04 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients |
| WO2026055168A1 (fr) | 2024-09-06 | 2026-03-12 | Surface Oncology, LLC | Anticorps anti-il-27, leurs utilisations et doses |
| WO2026055167A1 (fr) | 2024-09-05 | 2026-03-12 | Surface Oncology, LLC | Anticorps anti-il-27 et utilisation de biomarqueurs dans leurs utilisations |
| US12577621B2 (en) | 2020-09-08 | 2026-03-17 | Duke University | LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer |
| US12617846B2 (en) | 2021-05-06 | 2026-05-05 | Alexion Pharmaceuticals, Inc. | Subcutaneous (SC) administration of anti-C5 antibodies for treatment of complement-associated conditions |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
| US20060280774A1 (en) * | 1995-06-02 | 2006-12-14 | Allergan, Inc. | Compositions and methods for treating glaucoma |
| US6153231A (en) * | 1997-06-25 | 2000-11-28 | Wm. Wrigley Jr. Company | Environmentally friendly chewing gum bases |
| US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
| US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| DE60135352D1 (de) * | 2000-08-30 | 2008-09-25 | Univ Johns Hopkins | Vorrichtung zur intraokularen wirkstoffverabreichung |
| US6713081B2 (en) * | 2001-03-15 | 2004-03-30 | The United States Of America As Represented By The Department Of Health And Human Services | Ocular therapeutic agent delivery devices and methods for making and using such devices |
| US8246974B2 (en) * | 2003-05-02 | 2012-08-21 | Surmodics, Inc. | Medical devices and methods for producing the same |
| CA2524271C (fr) * | 2003-05-02 | 2012-09-04 | Surmodics, Inc. | Dispositif de relargage d'agent bioactif a liberation controlee |
| US20040253293A1 (en) * | 2003-06-16 | 2004-12-16 | Afshin Shafiee | Rate controlled release of a pharmaceutical agent in a biodegradable device |
| US20060141049A1 (en) * | 2003-11-12 | 2006-06-29 | Allergan, Inc. | Triamcinolone compositions for intravitreal administration to treat ocular conditions |
| US20080220049A1 (en) * | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
| US20060018949A1 (en) * | 2004-04-07 | 2006-01-26 | Bausch & Lomb Incorporated | Injectable biodegradable drug delivery system |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
| WO2005110374A1 (fr) | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Systemes de distribution de medicaments intraoculaires contenant un agent therapeutique, une cyclodextrine et un composant polymere |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
| US20050244465A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Drug delivery systems and methods for treatment of an eye |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8673341B2 (en) * | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20060182783A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Sustained release intraocular drug delivery systems |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
| US20050244469A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
| US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US8529927B2 (en) * | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
| US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244500A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intravitreal implants in conjuction with photodynamic therapy to improve vision |
| WO2005107708A1 (fr) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Implants d'inhibiteurs de tyrosine kinase intravitreens, biodegradables |
| US20060024350A1 (en) * | 2004-06-24 | 2006-02-02 | Varner Signe E | Biodegradable ocular devices, methods and systems |
| WO2006043965A1 (fr) * | 2004-10-14 | 2006-04-27 | Allergan, Inc. | Compositions ophtalmiques therapeutiques contenant des excipients sans danger pour la retine et leurs methodes |
| EP1824496A4 (fr) * | 2004-11-17 | 2008-07-16 | Joanne Mclaurin | Préparations comprenant des dérivés de scyllo-inositol et méthodes de traitement de troubles d agrégation protéinique |
| US20060233858A1 (en) * | 2005-03-08 | 2006-10-19 | Allergan, Inc. | Systems and methods providing targeted intraocular drug delivery |
| US7931909B2 (en) * | 2005-05-10 | 2011-04-26 | Allergan, Inc. | Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates |
| WO2007041855A1 (fr) * | 2005-10-13 | 2007-04-19 | Waratah Pharmaceuticals, Inc. | Derives de scyllo-inositol et leur utilisation dans le traitement de maladies caracterisees par le repliement anormal ou l'agregation anormale de proteines ou la formation, le depot, l'accumulation ou la persistance de la proteine amyloide |
| MX339797B (es) * | 2005-10-18 | 2016-06-10 | Allergan Inc | Terapia ocular que usa derivados glucocorticoides que penetran selectivamente los tejidos del segmento posterior. |
| US20070178138A1 (en) * | 2006-02-01 | 2007-08-02 | Allergan, Inc. | Biodegradable non-opthalmic implants and related methods |
| JP2009531283A (ja) | 2006-02-02 | 2009-09-03 | アラーガン、インコーポレイテッド | 眼系疾患の処置のための組成物および方法 |
| US20070197453A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Compositions and methods for treatment of disorders of protein aggregation |
| US20070197452A1 (en) * | 2006-02-17 | 2007-08-23 | Mclaurin Joanne | Treatment of amyloid-related diseases |
| CN103054837A (zh) * | 2006-03-09 | 2013-04-24 | 瓦拉塔药品公司 | 用于治疗蛋白积聚病症的环己烷多元醇制剂 |
| SG170816A1 (en) | 2006-03-31 | 2011-05-30 | Qlt Plug Delivery Inc | Drug delivery methods, structures, and compositions for nasolacrimal system |
| US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
| US7981096B2 (en) * | 2006-05-12 | 2011-07-19 | David Castillejos | Optic nerve head implant and medication delivery system |
| US20110028719A1 (en) * | 2006-05-19 | 2011-02-03 | Jacek Slon-Usakiewicz | Screening methods for amyloid beta modulators |
| US8668676B2 (en) * | 2006-06-19 | 2014-03-11 | Allergan, Inc. | Apparatus and methods for implanting particulate ocular implants |
| US7759304B2 (en) | 2006-06-21 | 2010-07-20 | Regents Of The University Of Colorado | Targeting complement factor H for treatment of diseases |
| US20070298073A1 (en) * | 2006-06-23 | 2007-12-27 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US9039761B2 (en) | 2006-08-04 | 2015-05-26 | Allergan, Inc. | Ocular implant delivery assemblies with distal caps |
| US20100173960A1 (en) * | 2006-09-21 | 2010-07-08 | Antonio Cruz | The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases |
| EP2068828A2 (fr) * | 2006-09-29 | 2009-06-17 | SurModics, Inc. | Implants oculaires biodégradables, et procédés pour traiter des maladies de l' il |
| US8586556B2 (en) | 2006-11-03 | 2013-11-19 | Allergan, Inc. | Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules |
| US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
| WO2008061373A1 (fr) * | 2006-11-24 | 2008-05-29 | Waratah Pharmaceuticals Inc. | Traitements par combinaison pour la maladie d'alzheimer et des maladies analogues |
| EP2091482A2 (fr) | 2006-12-01 | 2009-08-26 | Allergan, Inc. | Procédé pour déterminer des emplacements oculaires optimaux pour des systèmes d'administration de médicament |
| US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
| JP2010523602A (ja) | 2007-04-12 | 2010-07-15 | ワラタ ファーマシューティカルズ， インコーポレイテッド | 眼疾患の治療におけるシクロヘキサンヘキソール誘導体の使用 |
| CA2683546A1 (fr) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Utilisation de derives de cyclohexanehexol dans le traitement de .alpha.-synucleinopathies |
| CA2683580A1 (fr) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Utilisation de derives de cyclohexanehexol dans le traitement de la sclerose laterale amyotrophique |
| WO2008124930A1 (fr) * | 2007-04-12 | 2008-10-23 | Joanne Mclaurin | Utilisation de dérivés de cyclohexanehexol pour le traitement de maladies à répétition des polyglutamines |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| CA2704111C (fr) * | 2007-05-14 | 2017-06-20 | Sustained Nano Systems Llc | Particules hypercomprimees pour liberation controlee de medicaments ophtalmiques |
| JP4922213B2 (ja) | 2008-03-11 | 2012-04-25 | 本田技研工業株式会社 | 燃料直噴エンジン |
| CA2740124A1 (fr) * | 2008-10-09 | 2010-04-15 | Waratah Pharmaceuticals Inc. | Utilisation de scyllo-inositols pour le traitement de troubles lies a la degenerescence maculaire |
| US8034813B2 (en) * | 2008-11-18 | 2011-10-11 | Bausch & Lomb Incorporated | Polymorphs of brimonidine pamoate |
| US8551167B2 (en) | 2008-11-20 | 2013-10-08 | Insight Innovations, Llc | Intraocular implant cell migration inhibition system |
| US20120232649A1 (en) | 2008-11-20 | 2012-09-13 | Insight Innovations, Llc | Intraocular Lens Cell Migration Inhibition System |
| US9943402B2 (en) | 2008-11-20 | 2018-04-17 | Insight Innovations, Llc | Micropatterned intraocular implant |
| NZ592645A (en) * | 2008-11-20 | 2013-01-25 | Insight Innovations Llc | Biocompatible biodegradable intraocular implant system |
| US9308070B2 (en) | 2008-12-15 | 2016-04-12 | Allergan, Inc. | Pliable silk medical device |
| US8545554B2 (en) * | 2009-01-16 | 2013-10-01 | Allergan, Inc. | Intraocular injector |
| US20110111031A1 (en) * | 2009-04-20 | 2011-05-12 | Guang-Liang Jiang | Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof |
| MX351261B (es) | 2012-06-01 | 2017-10-06 | Surmodics Inc | Aparato y método para recubrir catéteres con globo. |
| US9827401B2 (en) | 2012-06-01 | 2017-11-28 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
| CN105188733B (zh) | 2013-03-13 | 2020-05-08 | 建新公司 | 包含pdgf和vegf结合部分的融合蛋白及其使用方法 |
| WO2014179568A2 (fr) | 2013-05-02 | 2014-11-06 | Odin Biotech | Implant oculaire à deux couches |
| JP6655074B2 (ja) | 2014-06-20 | 2020-02-26 | ジェネンテック， インコーポレイテッド | シャガシンに基づく足場組成物、方法及び使用 |
| WO2017173327A1 (fr) | 2016-03-31 | 2017-10-05 | The Schepens Eye Research Institute, Inc. | Inhibiteur de l'endomucine utilisé comme agent anti-angiogénique |
| EP4520828A3 (fr) | 2016-11-15 | 2025-07-09 | The Schepens Eye Research Institute, Inc. | Compositions et procédés pour le traitement de l'angiogenèse aberrante |
| WO2019033119A1 (fr) | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | Traitement d'états ophtalmiques tels que la dégénérescence maculaire, le glaucome et la rétinopathie diabétique à l'aide d'agents pharmaceutiques qui éliminent les cellules sénescentes |
| WO2019070917A1 (fr) | 2017-10-03 | 2019-04-11 | The Schepens Eye Research Institute, Inc. | Composés et compositions pour inhiber la dégénérescence de l'épithélium pigmentaire rétinien et procédés les utilisant |
| US11739326B2 (en) | 2017-11-14 | 2023-08-29 | Massachusetts Eye And Ear Infirmary | RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition |
| WO2020112816A1 (fr) | 2018-11-29 | 2020-06-04 | Surmodics, Inc. | Appareil et méthodes de revêtement de dispositifs médicaux |
| US11819590B2 (en) | 2019-05-13 | 2023-11-21 | Surmodics, Inc. | Apparatus and methods for coating medical devices |
| US12496612B2 (en) | 2021-01-08 | 2025-12-16 | Surmodics, Inc. | Coating application system and methods for coating rotatable medical devices |
| US20250049758A1 (en) | 2021-12-06 | 2025-02-13 | Breye Therapeutics Aps | Danegaptide Formulation for Application in the Eye |
| KR20260039752A (ko) | 2023-07-13 | 2026-03-20 | 크리야 테라퓨틱스, 인크. | 보체 경로 억제제 융합체 및 그의 사용 방법 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0108661A1 (fr) * | 1982-10-04 | 1984-05-16 | Merck & Co. Inc. | Insertions oculaires en hydroxypropyl cellulose stabilisées et procédé de stérilisation |
| EP0430539A2 (fr) * | 1989-11-22 | 1991-06-05 | Visionex, Inc. | Insert ophtalmique |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4135514A (en) * | 1974-12-23 | 1979-01-23 | Alza Corporation | Osmotic releasing system for administering ophthalmic drug to eye of animal |
| US4853224A (en) * | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
-
1991
- 1991-11-22 KR KR1019910020940A patent/KR0185215B1/ko not_active Expired - Fee Related
- 1991-11-26 JP JP03337591A patent/JP3116489B2/ja not_active Expired - Fee Related
- 1991-11-27 US US07/799,249 patent/US5501856A/en not_active Expired - Lifetime
- 1991-11-28 CA CA002056513A patent/CA2056513A1/fr not_active Abandoned
- 1991-11-29 EP EP91120586A patent/EP0488401A1/fr not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0108661A1 (fr) * | 1982-10-04 | 1984-05-16 | Merck & Co. Inc. | Insertions oculaires en hydroxypropyl cellulose stabilisées et procédé de stérilisation |
| EP0430539A2 (fr) * | 1989-11-22 | 1991-06-05 | Visionex, Inc. | Insert ophtalmique |
Cited By (225)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0654256A4 (fr) * | 1993-02-26 | 1995-01-04 | Santen Pharmaceutical Co Ltd | Bouchon de sclerotique biodegradable. |
| US5707643A (en) * | 1993-02-26 | 1998-01-13 | Santen Pharmaceutical Co., Ltd. | Biodegradable scleral plug |
| WO1996013286A3 (fr) * | 1994-10-26 | 1996-06-20 | Houston Biotechnology | Procedes et compositions de modulation de la proliferation cellulaire et de la cicatrisation |
| US5618553A (en) * | 1994-10-26 | 1997-04-08 | Houston Biotechnology Incorporated | Methods and compositions for the modulation of cell proliferation and wound healing |
| US6063396A (en) * | 1994-10-26 | 2000-05-16 | Houston Biotechnology Incorporated | Methods and compositions for the modulation of cell proliferation and wound healing |
| US6063116A (en) * | 1994-10-26 | 2000-05-16 | Medarex, Inc. | Modulation of cell proliferation and wound healing |
| EP1637164A2 (fr) * | 1995-06-02 | 2006-03-22 | Allergan, Inc. | Amélioration apportée à une formulation destinée à la libération contrôlée des médicaments par combinaison d'agents hydrophiles et hydrophobes |
| EP2298353A1 (fr) * | 1995-06-02 | 2011-03-23 | Allergan, Inc. | Amélioration apportée à une formulation destinée à la libération controlée des médicaments par combinaison d'agents hydrophiles et hydrophobes |
| WO1997028833A1 (fr) * | 1996-02-12 | 1997-08-14 | Houston Biotechnology Incorporated | Procedes et compositions de modulation de la proliferation cellulaire et de cicatrisation de lesions |
| EP0992244A4 (fr) * | 1997-07-02 | 2001-01-17 | Santen Pharmaceutical Co Ltd | Bouchons scleraux d'acide polylactique |
| US6488938B1 (en) | 1997-07-02 | 2002-12-03 | Santen Pharmaceutical Co., Ltd. | Polylactic acid scleral plug |
| WO2002002076A3 (fr) * | 2000-07-05 | 2002-07-04 | Oculex Pharm Inc | Procedes servant a traiter des etats inflammatoires de l'oeil |
| US9012437B2 (en) | 2000-07-05 | 2015-04-21 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
| US8242099B2 (en) | 2000-07-05 | 2012-08-14 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
| US9775849B2 (en) | 2000-07-05 | 2017-10-03 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
| EP1637126A3 (fr) * | 2000-07-05 | 2009-10-21 | Allergan, Inc. | Méthodes de traitement des inflammations de l'oeil |
| EP3167872A1 (fr) * | 2000-07-05 | 2017-05-17 | Allergan, Inc. | Procédés de traitement des états inflammatoires de l' oeil |
| US10206934B2 (en) | 2000-07-05 | 2019-02-19 | Allergan, Inc. | Implants and methods for treating inflammation-mediated conditions of the eye |
| US9592242B2 (en) | 2000-11-29 | 2017-03-14 | Allergan, Inc. | Methods for treating edema in the eye and intraocular implants for use therefor |
| EP1621219A3 (fr) * | 2000-11-29 | 2006-03-22 | Allergan, Inc. | Implants intra-oculaires pour la prévention du rejet de greffe de l'oeil |
| US7033605B2 (en) | 2000-11-29 | 2006-04-25 | Allergan, Inc. | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| AU2006201271B2 (en) * | 2000-11-29 | 2006-08-24 | Allergan, Inc. | Intraocular implants for preventing transplant rejection in the eye |
| US8043628B2 (en) | 2000-11-29 | 2011-10-25 | Allergan, Inc. | Methods for reducing edema |
| US8828446B2 (en) | 2000-11-29 | 2014-09-09 | Allergan, Inc. | Method for reducing transplant rejection in the eye and intraocular implants for use therefor |
| US7625582B2 (en) | 2000-11-29 | 2009-12-01 | Allergan, Inc. | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US9283178B2 (en) | 2000-11-29 | 2016-03-15 | Allergan, Inc. | Methods for treating edema in the eye and intraocular implants for use therefor |
| US7767223B2 (en) | 2000-11-29 | 2010-08-03 | Allergan, Inc. | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use |
| EP1550471A1 (fr) * | 2000-11-29 | 2005-07-06 | Allergan Inc. | Implants intra-oculaires pour la prévention du rejet de greffe dans l'oeil |
| US8088407B2 (en) | 2000-11-29 | 2012-01-03 | Allergan, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US8071120B2 (en) | 2000-11-29 | 2011-12-06 | Allergan, Inc. | Methods for treating neovascularization and intravitreal implants |
| US7846468B2 (en) | 2000-11-29 | 2010-12-07 | Allergan, Inc. | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| US6699493B2 (en) | 2000-11-29 | 2004-03-02 | Oculex Pharmaceuticals, Inc. | Method for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
| WO2002078713A1 (fr) * | 2001-03-28 | 2002-10-10 | Santen Pharmaceutical Co., Ltd. | Medicaments contre les affections retiniennes et choroidiennes contenant des steroides comme principe actif |
| US8034370B2 (en) | 2003-01-09 | 2011-10-11 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US10702539B2 (en) | 2003-01-09 | 2020-07-07 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| WO2004062649A3 (fr) * | 2003-01-09 | 2004-11-04 | Allergan Inc | Implant oculaire biodegradable |
| US8034366B2 (en) | 2003-01-09 | 2011-10-11 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8506987B2 (en) | 2003-01-09 | 2013-08-13 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US9192511B2 (en) | 2003-01-09 | 2015-11-24 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8048445B2 (en) | 2003-01-09 | 2011-11-01 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8778381B2 (en) | 2003-01-09 | 2014-07-15 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US10076526B2 (en) | 2003-01-09 | 2018-09-18 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8318070B2 (en) | 2003-01-09 | 2012-11-27 | Allergan, Inc. | Ocular implant made by a double extrusion process |
| US8846094B2 (en) | 2003-11-12 | 2014-09-30 | Allergan, Inc. | Peripherally administered viscous formulations |
| US9265775B2 (en) | 2003-11-12 | 2016-02-23 | Allergan, Inc. | Pharmaceutical compositions |
| US9089478B2 (en) | 2003-11-12 | 2015-07-28 | Allergen, Inc. | Peripherally administered viscous formulations |
| US9328157B2 (en) | 2003-12-05 | 2016-05-03 | Bristol-Myers Squibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
| US9862758B2 (en) | 2003-12-05 | 2018-01-09 | Bristol-Myers Quibb Company | Inhibitors of type 2 vascular endothelial growth factor receptors |
| US10995131B2 (en) | 2003-12-05 | 2021-05-04 | Bristol-Myers Squibb Company | Libraries of modified fibronectin type III tenth domain-containing polypeptides |
| US8609613B2 (en) | 2003-12-05 | 2013-12-17 | Bristol-Myers Squibb Company | Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides |
| US9572859B2 (en) | 2004-01-20 | 2017-02-21 | Allergan, Inc. | Compositions and methods for localized therapy of the eye |
| US10874605B2 (en) | 2004-04-30 | 2020-12-29 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8895049B2 (en) | 2004-04-30 | 2014-11-25 | Allergan, Inc. | Extended release biodegradable ocular implants |
| EP2361617A1 (fr) * | 2004-04-30 | 2011-08-31 | Allergan, Inc. | Implants intra-oculaires à libération prolongée comprenant un antagoniste du récepteur bêta-adrénergique et procédés pour le traitement de neuropathies |
| US8298570B2 (en) | 2004-04-30 | 2012-10-30 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8580292B2 (en) | 2004-04-30 | 2013-11-12 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US10201641B2 (en) | 2004-04-30 | 2019-02-12 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US8263110B2 (en) | 2004-04-30 | 2012-09-11 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8685435B2 (en) | 2004-04-30 | 2014-04-01 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8715709B2 (en) | 2004-04-30 | 2014-05-06 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| US8257730B2 (en) | 2004-04-30 | 2012-09-04 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8771722B2 (en) | 2004-04-30 | 2014-07-08 | Allergan, Inc. | Methods of treating ocular disease using steroid-containing sustained release intraocular implants |
| US8974812B2 (en) | 2004-04-30 | 2015-03-10 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US10154960B2 (en) | 2004-04-30 | 2018-12-18 | Allergan, Inc. | Extended release biodegradable ocular implants |
| US8962009B2 (en) | 2004-04-30 | 2015-02-24 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| WO2005110380A1 (fr) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Implants intraoculaires a liberation soutenue contenant un antagoniste du recepteur beta-adrenergique et methodes de traitement de neuropathies oculaires |
| EP2777693A1 (fr) | 2004-04-30 | 2014-09-17 | Allergan, Inc. | Les implants oculaires biodégradables avec les caractéristiques à une libération prolongée |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| WO2005110366A1 (fr) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Derive d'estradiol, derive d'estratopone contenant un implant intra-oculaire a liberation prolongee et leurs procedes de fabrication |
| US8440216B2 (en) | 2004-04-30 | 2013-05-14 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| AU2005271700B2 (en) * | 2004-07-12 | 2010-11-11 | Allergan, Inc. | Opthalmic compositions and methods for treating ophthalmic conditions |
| AU2013221985B2 (en) * | 2004-07-12 | 2016-09-01 | Allergan, Inc. | Ophthalmic compositions and methods for treating ophthalmic conditions |
| WO2006017347A2 (fr) | 2004-07-12 | 2006-02-16 | Allergan, Inc. | Compositions ophtalmiques et procédés de traitement de conditions ophtalmiques |
| EP2216026A1 (fr) * | 2004-07-12 | 2010-08-11 | Allergan, Inc. | Compositions ophthalmologiques et leur utilisation pour le traitement des maladies oculaires. |
| WO2006017347A3 (fr) * | 2004-07-12 | 2006-04-13 | Allergan Inc | Compositions ophtalmiques et procédés de traitement de conditions ophtalmiques |
| AU2011200584B2 (en) * | 2004-07-12 | 2013-05-30 | Allergan, Inc. | Ophthalmic compositions and methods for treating ophthalmic conditions |
| EP2329811A1 (fr) | 2004-08-13 | 2011-06-08 | Allergan, Inc. | Implant oculaire fabriqué par un procédé d'extrusion multiple |
| US9110064B2 (en) | 2005-02-28 | 2015-08-18 | The Regents Of The University Of California | Methods for diagnosis and treatment of endometrial cancer |
| US9624304B2 (en) | 2005-04-15 | 2017-04-18 | The Regents Of The University Of California | Antibodies which bind to epithelial membrane protein 2 (EMP2) |
| US9011857B2 (en) | 2005-04-15 | 2015-04-21 | The Regents Of The University Of California | Methods of treating cancer by administering EMP2 antibodies |
| US8802128B2 (en) | 2006-06-23 | 2014-08-12 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| WO2008020087A1 (fr) | 2006-08-08 | 2008-02-21 | Fundacion Inasmet | Système optique implantable, son procédé de mise au point et ses applications |
| US10221232B2 (en) | 2006-11-22 | 2019-03-05 | Bristol-Myers Squibb Company | Methods of treating cancer by administering IGF-IR binding molecules |
| US11149077B2 (en) | 2006-11-22 | 2021-10-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
| EP2218424A1 (fr) | 2006-12-01 | 2010-08-18 | Allergan, Inc. | Dispositif pour l'administration intraoculaire d'un médicament |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| US8956655B2 (en) | 2007-05-24 | 2015-02-17 | Allergan, Inc. | Biodegradable drug delivery system |
| US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
| US9464135B2 (en) | 2007-10-08 | 2016-10-11 | The Regents Of The University Of California | Epithelial membrane protein-2 (EMP2) and proliferative vitroretinopathy (PVR) |
| US10781247B2 (en) | 2008-02-14 | 2020-09-22 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| US9234028B2 (en) | 2008-02-14 | 2016-01-12 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| US9920108B2 (en) | 2008-02-14 | 2018-03-20 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins that bind EGFR |
| US9902762B2 (en) | 2008-05-22 | 2018-02-27 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| US10774130B2 (en) | 2008-05-22 | 2020-09-15 | Bristol-Myers Squibb Company | Method of treating cancer by administering multivalent fibronectin based scaffold domain proteins |
| US8728483B2 (en) | 2008-05-22 | 2014-05-20 | Bristol-Myers Squibb Company | Multivalent fibronectin based scaffold domain proteins |
| EP2664347A1 (fr) | 2008-07-18 | 2013-11-20 | Allergan, Inc. | Procédé de traitement de la dégénérescence maculaire liée à l'âge atrophique |
| US10363214B2 (en) | 2008-07-18 | 2019-07-30 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| EP3524270A1 (fr) | 2008-07-18 | 2019-08-14 | Allergan, Inc. | Procédé de traitement de la dégénérescence maculaire liée à l'âge atrophique |
| US8821870B2 (en) | 2008-07-18 | 2014-09-02 | Allergan, Inc. | Method for treating atrophic age related macular degeneration |
| EP3950002A1 (fr) | 2008-07-18 | 2022-02-09 | Allergan, Inc. | Composition à utiliser dans le traitement de la dégénérescence maculaire atrophique liée à l'âge |
| WO2010054403A1 (fr) | 2008-11-10 | 2010-05-14 | Alexion Pharmaceuticals, Inc. | Procédés et compositions pour le traitement de troubles associés au complément |
| EP3101031A1 (fr) | 2008-11-10 | 2016-12-07 | Alexion Pharmaceuticals, Inc. | Procédés et compositions de traitement de troubles associés à un complément |
| EP3974448A1 (fr) | 2008-11-10 | 2022-03-30 | Alexion Pharmaceuticals, Inc. | Procédés et compositions de traitement de troubles associés à un complément |
| EP2894165A1 (fr) | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Procédés et compositions pour le traitement de troubles associés à un complément |
| EP2894166A1 (fr) | 2008-11-10 | 2015-07-15 | Alexion Pharmaceuticals, Inc. | Procédés et compositions pour le traitement de troubles associés à un complément |
| EP3121197A1 (fr) | 2008-11-10 | 2017-01-25 | Alexion Pharmaceuticals, Inc. | Procédés et compositions de traitement de troubles associés à un complément |
| US10842739B2 (en) | 2008-11-17 | 2020-11-24 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US10471004B2 (en) | 2008-11-17 | 2019-11-12 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US9861576B2 (en) | 2008-11-17 | 2018-01-09 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| US10954286B2 (en) | 2008-11-24 | 2021-03-23 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
| US9017655B2 (en) | 2008-11-24 | 2015-04-28 | Bristol-Myers Squibb Company | Bispecific EGFR/IGFIR binding molecules |
| US9771411B2 (en) | 2008-11-24 | 2017-09-26 | Bristol-Myers Squibb Company | Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules |
| US10183987B2 (en) | 2008-11-24 | 2019-01-22 | Bristol-Myers Squibb Company | Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules |
| EP2752427A1 (fr) | 2009-02-24 | 2014-07-09 | Alexion Pharmaceuticals, Inc. | Anticorps contenant des peptides mimétiques TPO/EPO thérapeutiques |
| WO2010151526A1 (fr) | 2009-06-23 | 2010-12-29 | Alexion Pharmaceuticals, Inc. | Anticorps bispécifiques se liant aux protéines du complément |
| US9138480B2 (en) | 2009-11-09 | 2015-09-22 | Allergan, Inc. | Compositions and methods for stimulating hair growth |
| WO2011103599A2 (fr) | 2010-02-19 | 2011-08-25 | The Regents Of The Universith Of California | Réactifs de liaison de la protéine membranaire épithéliale 2 (emp2) et leurs utilisations thérapeutiques dans des maladies oculaires |
| US11407821B2 (en) | 2010-04-30 | 2022-08-09 | Alexion Pharmaceuticals, Inc. | Anti-C5A antibodies |
| US9963503B2 (en) | 2010-04-30 | 2018-05-08 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5a antibodies |
| US9309310B2 (en) | 2010-04-30 | 2016-04-12 | Alexion Pharmaceuticals, Inc. | Nucleic acids encoding anti-C5a antibodies |
| EP2824111A2 (fr) | 2010-04-30 | 2015-01-14 | Alexion Pharmaceuticals, Inc. | Anticorps anti-C5A et leurs procédés d'utilisation de ces anticorps |
| US9371378B1 (en) | 2010-04-30 | 2016-06-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
| US10450370B2 (en) | 2010-04-30 | 2019-10-22 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
| US9011852B2 (en) | 2010-04-30 | 2015-04-21 | Alexion Pharmaceuticals, Inc. | Anti-C5a antibodies |
| US9221901B2 (en) | 2010-04-30 | 2015-12-29 | Alexion Pharmaceuticals, Inc. | Methods of treating complement-associated disorders with anti-C5a antibodies |
| US9434784B1 (en) | 2010-04-30 | 2016-09-06 | Alexion Pharmaceuticals, Inc. | Nucleic acids encodng anti-C5A antibodies |
| WO2011137395A1 (fr) | 2010-04-30 | 2011-11-03 | Rother Russell P | Anticorps anti-c5a et méthodes pour utiliser les anticorps |
| US9469690B2 (en) | 2010-04-30 | 2016-10-18 | Alexion Pharmaceuticals, Inc. | Methods of treating complement-associated disorders with anti-C5a antibodies |
| US11161893B2 (en) | 2010-05-26 | 2021-11-02 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| US9562089B2 (en) | 2010-05-26 | 2017-02-07 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| US10273286B2 (en) | 2010-05-26 | 2019-04-30 | Bristol-Myers Squibb Company | Fibronectin based scaffold proteins having improved stability |
| US9815890B2 (en) | 2010-06-22 | 2017-11-14 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3d fragment of complement component 3 |
| USRE49339E1 (en) | 2010-06-22 | 2022-12-20 | The Regents Of The University Of Colorado, A Body Corporate | Antibodies to the C3D fragment of complement component 3 |
| WO2012106634A1 (fr) | 2011-02-03 | 2012-08-09 | Alexion Pharmaceuticals, Inc. | Utilisation d'un anticorps anti-cd200 pour prolonger la survie d'allogreffes |
| US9259488B2 (en) | 2012-08-17 | 2016-02-16 | The Regents Of The University Of Colorado, A Body Corporate | Anti-C3d antibody conjugates and methods of detecting complement activation |
| US11191851B2 (en) | 2012-08-17 | 2021-12-07 | Musc Foundation For Research Development | Anti-C3d antibody conjugates and methods of detecting complement activation |
| US9610246B2 (en) | 2013-02-15 | 2017-04-04 | Allergan, Inc. | Sustained drug delivery implant |
| US10231926B2 (en) | 2013-02-15 | 2019-03-19 | Allergan, Inc. | Sustained drug delivery implant |
| EP3473272A1 (fr) | 2013-03-29 | 2019-04-24 | Alexion Pharmaceuticals, Inc. | Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire |
| WO2014160958A1 (fr) | 2013-03-29 | 2014-10-02 | Alexion Pharmaceuticals, Inc. | Compositions et procédés pour augmenter la demi-vie sérique d'un agent thérapeutique ciblant c5 complémentaire |
| EP4300103A2 (fr) | 2013-08-07 | 2024-01-03 | Alexion Pharmaceuticals, Inc. | Protéines de bio-marqueurs de syndrome hémolytique et urémique atypique |
| EP3290922A1 (fr) | 2013-08-07 | 2018-03-07 | Alexion Pharmaceuticals, Inc. | Protéines de bio-marqueurs de syndrome hémolytique et urémique atypique |
| US11434280B2 (en) | 2014-03-07 | 2022-09-06 | Alexion Pharmaceuticals, Inc. | Anti-C5 antibodies having improved pharmacokinetics |
| US9803007B1 (en) | 2014-03-07 | 2017-10-31 | Alexion Pharmaceuticals, Inc. | Anti-C5 antibodies having improved pharmacokinetics |
| US9663574B2 (en) | 2014-03-07 | 2017-05-30 | Alexion Pharmaceuticals, Inc. | Anti-C5 antibodies having improved pharmacokinetics |
| US10227400B2 (en) | 2014-03-07 | 2019-03-12 | Alexion Pharmaceuticals, Inc. | Methods of treating atypical hemolytic uremic syndrome with anti-C5 antibodies |
| US9371377B2 (en) | 2014-03-07 | 2016-06-21 | Alexion Pharmaceuticals, Inc. | Anti-C5 antibodies having improved pharmacokinetics |
| WO2015134894A1 (fr) | 2014-03-07 | 2015-09-11 | Alexion Pharmaceuticals, Inc. | Anticorps anti-c5 présentant une pharmacocinétique améliorée |
| US9206251B2 (en) | 2014-03-07 | 2015-12-08 | Alexion Pharmaceuticals, Inc. | Nucleic acids encoding anti-C5 antibodies having improved pharmacokinetics |
| US10584164B2 (en) | 2014-03-07 | 2020-03-10 | Alexion Pharmaceuticals, Inc. | Methods of treating atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria with anti-C5 antibodies |
| EP3095795A1 (fr) | 2014-03-07 | 2016-11-23 | Alexion Pharmaceuticals, Inc. | Anticorps anti-c5 présentant une pharmacocinétique améliorée |
| US9079949B1 (en) | 2014-03-07 | 2015-07-14 | Alexion Pharmaceuticals, Inc. | Anti-C5 antibodies having improved pharmacokinetics |
| EP3594235A1 (fr) | 2014-03-07 | 2020-01-15 | Alexion Pharmaceuticals, Inc. | Anticorps anti-c5 présentant une pharmacocinétique améliorée |
| US9107861B1 (en) | 2014-03-07 | 2015-08-18 | Alexion Pharmaceuticals, Inc. | Methods of treating C5 mediated complement-associated conditions with anti-C5 antibodies having improved pharmacokinetics |
| WO2016054522A1 (fr) | 2014-10-03 | 2016-04-07 | Ntercept, Llc | Compositions et procédés pour inhiber l'activité biologique de biomolécules solubles |
| WO2016123454A1 (fr) | 2015-01-29 | 2016-08-04 | Board Of Trustees Of Miching State University | Polypeptides cryptiques et leurs utilisations |
| US10627415B2 (en) | 2015-03-12 | 2020-04-21 | Board Of Trustees Of Michigan State University | Compositions and methods for diagnosing, monitoring, and treating an autoimmune disease |
| EP3736287A1 (fr) | 2015-05-11 | 2020-11-11 | The Johns Hopkins University | Anticorps auto-immuns destinés à être utilisés pour inhiber la croissance de cellules cancéreuses |
| US11938183B2 (en) | 2015-05-11 | 2024-03-26 | The Johns Hopkins University | Autoimmune antibodies for use in inhibiting cancer cell growth |
| WO2017176762A1 (fr) | 2016-04-06 | 2017-10-12 | Nanotics, Llc | Particules comprenant des sous-particules ou des échafaudages d'acide nucléique |
| US12459992B2 (en) | 2016-05-27 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| WO2018236904A1 (fr) | 2017-06-19 | 2018-12-27 | Surface Oncology, Inc. | Combinaison d'anticorps anti-cd47 et d'agents induisant la mort cellulaire, et leurs utilisations |
| WO2019014328A2 (fr) | 2017-07-11 | 2019-01-17 | Compass Therapeutics Llc | Anticorps agonistes qui lient cd137 humain et leurs utilisations |
| US11752207B2 (en) | 2017-07-11 | 2023-09-12 | Compass Therapeutics Llc | Agonist antibodies that bind human CD137 and uses thereof |
| EP4218813A2 (fr) | 2017-07-27 | 2023-08-02 | Alexion Pharmaceuticals, Inc. | Formules d'anticorps anti-c5 à haute concentration |
| US11365241B2 (en) | 2017-07-27 | 2022-06-21 | Alexion Pharmaceuticals, Inc. | High concentration anti-C5 antibody formulations |
| WO2019023564A1 (fr) | 2017-07-27 | 2019-01-31 | Alexion Pharmaceutical, Inc. | Formules d'anticorps anti-c5 à haute concentration |
| US12012448B2 (en) | 2017-07-27 | 2024-06-18 | Alexion Pharmaceuticals, Inc. | High concentration anti-C5 antibody formulations |
| WO2019036605A2 (fr) | 2017-08-17 | 2019-02-21 | Massachusetts Institute Of Technology | Agents de liaison à spécificité multiple de chimiokines cxc et leurs utilisations |
| US11642395B2 (en) | 2017-09-08 | 2023-05-09 | Bristol-Myers Squibb Company | Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH) |
| WO2019051073A1 (fr) | 2017-09-08 | 2019-03-14 | Bristol-Myers Squibb Company | Facteur de croissance des fibroblastes 21 (fgf-21) modifié destiné à une utilisation dans des méthodes de traitement de la stéatohépatite non alcoolique (nash) |
| WO2019067499A1 (fr) | 2017-09-27 | 2019-04-04 | Alexion Pharmaceuticals, Inc. | Signature de biomarqueur pour la prédiction d'une réponse tumorale vis-à-vis d'une thérapie anti-cd200 |
| US12128101B2 (en) | 2017-10-26 | 2024-10-29 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) |
| US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
| US12286483B2 (en) | 2017-10-31 | 2025-04-29 | Compass Therapeutics Llc | Method of treating cancer using CD137 antibodies and PD-1 antagonists |
| WO2019089753A2 (fr) | 2017-10-31 | 2019-05-09 | Compass Therapeutics Llc | Anticorps cd137 et antagonistes pd-1 et leurs utilisations |
| US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
| WO2019100052A2 (fr) | 2017-11-20 | 2019-05-23 | Compass Therapeutics Llc | Anticorps cd137 et anticorps ciblant un antigène tumoral et leurs utilisations |
| US10738128B2 (en) | 2018-03-14 | 2020-08-11 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
| US10793637B2 (en) | 2018-03-14 | 2020-10-06 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
| EP4043496A1 (fr) | 2018-03-14 | 2022-08-17 | Surface Oncology, Inc. | Anticorps qui se lient à cd39 et leurs utilisations |
| WO2019178269A2 (fr) | 2018-03-14 | 2019-09-19 | Surface Oncology, Inc. | Anticorps qui se lient à cd39 et leurs utilisations |
| US11332524B2 (en) | 2018-03-22 | 2022-05-17 | Surface Oncology, Inc. | Anti-IL-27 antibodies and uses thereof |
| WO2019200357A1 (fr) | 2018-04-12 | 2019-10-17 | Surface Oncology, Inc. | Biomarqueur pour agents thérapeutiques ciblant cd47 et leurs utilisations |
| WO2019204743A1 (fr) | 2018-04-19 | 2019-10-24 | Checkmate Pharmaceuticals, Inc. | Agonistes de récepteur de type rig-i synthétique |
| WO2019226658A1 (fr) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions multispécifiques de liaison à l'antigène et procédés d'utilisation |
| WO2019226617A1 (fr) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Compositions et procédés pour améliorer la destruction de cellules cibles par des lymphocytes nk |
| US12404320B2 (en) | 2018-05-31 | 2025-09-02 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patients |
| US12460012B2 (en) | 2018-06-04 | 2025-11-04 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patients |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| WO2020018715A1 (fr) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Protéines de fusion à base d'échafaudage d'immunoglobuline multimère soluble et leurs utilisations |
| WO2020033926A2 (fr) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Anticorps qui se lient à cd277 et leurs utilisations |
| WO2020033925A2 (fr) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Anticorps qui se lient à cd277 et leurs utilisations |
| WO2020033923A1 (fr) | 2018-08-09 | 2020-02-13 | Compass Therapeutics Llc | Agents de liaison à l'antigène qui se lient à cd277 et leurs utilisations |
| US12240893B2 (en) | 2018-10-30 | 2025-03-04 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) |
| US12251364B2 (en) | 2018-11-06 | 2025-03-18 | Georgetown University | Treating non-alcoholic steatohepatitis with cck inhibitors |
| WO2020097054A1 (fr) | 2018-11-06 | 2020-05-14 | Georgetown University | Traitement de la stéatohépatite non alcoolique avec des inhibiteurs de la cck |
| US11046769B2 (en) | 2018-11-13 | 2021-06-29 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| US12503511B2 (en) | 2018-11-13 | 2025-12-23 | Compass Therapeutics, LLC | Multispecific binding constructs against checkpoint molecules and uses thereof |
| US11970538B2 (en) | 2018-11-13 | 2024-04-30 | Compass Therapeutics Llc | Multispecific binding constructs against checkpoint molecules and uses thereof |
| US12358978B2 (en) | 2018-12-13 | 2025-07-15 | Surface Oncology, LLC | Anti-IL-27 antibodies and uses thereof |
| WO2020150496A1 (fr) | 2019-01-16 | 2020-07-23 | Compass Therapeutics Llc | Formulations d'anticorps qui se lient au cd137 humain et leurs utilisations |
| WO2020163782A2 (fr) | 2019-02-08 | 2020-08-13 | The Uab Research Foundation | Composition pour le traitement et la prévention de la maladie inflammatoire chronique de l'intestin |
| US11655303B2 (en) | 2019-09-16 | 2023-05-23 | Surface Oncology, Inc. | Anti-CD39 antibody compositions and methods |
| WO2021062244A1 (fr) | 2019-09-25 | 2021-04-01 | Surface Oncology, Inc. | Anticorps anti-il-27 et leurs utilisations |
| WO2021067526A1 (fr) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Inhibiteurs du complément pour le traitement d'une réponse médiée par le complément induite par un médicament |
| WO2021081353A1 (fr) | 2019-10-23 | 2021-04-29 | Checkmate Pharmaceuticals, Inc. | Agonistes de récepteur du type rig-i synthétiques |
| WO2021080682A1 (fr) | 2019-10-24 | 2021-04-29 | Massachusetts Institute Of Technology | Anticorps monoclonaux qui se lient au cd161 humain et leurs utilisations |
| US12084509B2 (en) | 2020-04-30 | 2024-09-10 | Duke University | Gene signatures for monitoring acute rejection and methods of using same |
| WO2021231720A1 (fr) | 2020-05-15 | 2021-11-18 | Alexion Pharmaceuticals, Inc. | Méthode d'utilisation de vésicules extracellulaires pour détecter une activation du complément, et leurs utilisations pour l'évaluation et/ou la surveillance du traitement d'une maladie à médiation par le complément |
| US12577621B2 (en) | 2020-09-08 | 2026-03-17 | Duke University | LRRK2 mutations as biomarkers for the prediction of immune checkpoint response in cancer |
| US12617846B2 (en) | 2021-05-06 | 2026-05-05 | Alexion Pharmaceuticals, Inc. | Subcutaneous (SC) administration of anti-C5 antibodies for treatment of complement-associated conditions |
| WO2022236134A1 (fr) | 2021-05-07 | 2022-11-10 | Surface Oncology, Inc. | Anticorps anti-il-27 et leurs utilisations |
| US12577299B2 (en) | 2021-05-07 | 2026-03-17 | Surface Oncology, LLC | Anti-IL-27 antibodies and uses thereof |
| WO2022251446A1 (fr) | 2021-05-28 | 2022-12-01 | Alexion Pharmaceuticals, Inc. | Procédés de détection de biomarqueurs cm-tma |
| WO2023230128A1 (fr) | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Utilisation d'anticorps anti-il-27 |
| WO2023230116A1 (fr) | 2022-05-25 | 2023-11-30 | Surface Oncology, Inc. | Utilisation d'anticorps anti-il-27 |
| WO2024054436A1 (fr) | 2022-09-06 | 2024-03-14 | Alexion Pharmaceuticals, Inc. | Profils de biomarqueurs de diagnostic et de pronostic chez des patients ayant une microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) |
| EP4697024A2 (fr) | 2022-09-06 | 2026-02-18 | Alexion Pharmaceuticals, Inc. | Profils de biomarqueurs de diagnostic et de pronostic chez des patients ayant une microangiopathie thrombotique associée à une greffe de cellules souches hématopoïétiques (hsct-tma) |
| WO2024238421A1 (fr) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Utilisation de biomarqueurs pour l'identification et le traitement de troubles médiées par le complément |
| WO2024238422A1 (fr) | 2023-05-12 | 2024-11-21 | Alexion Pharmaceuticals, Inc. | Utilisation d'un panel de lectines pour la détection de biomarqueurs du complément dans des vésicules extracellulaires d'urine |
| WO2026055167A1 (fr) | 2024-09-05 | 2026-03-12 | Surface Oncology, LLC | Anticorps anti-il-27 et utilisation de biomarqueurs dans leurs utilisations |
| WO2026055168A1 (fr) | 2024-09-06 | 2026-03-12 | Surface Oncology, LLC | Anticorps anti-il-27, leurs utilisations et doses |
Also Published As
| Publication number | Publication date |
|---|---|
| JP3116489B2 (ja) | 2000-12-11 |
| JPH0517370A (ja) | 1993-01-26 |
| CA2056513A1 (fr) | 1992-05-31 |
| KR920009385A (ko) | 1992-06-25 |
| US5501856A (en) | 1996-03-26 |
| KR0185215B1 (ko) | 1999-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5501856A (en) | Controlled-release pharmaceutical preparation for intra-ocular implant | |
| Kimura et al. | A new model of subretinal neovascularization in the rabbit. | |
| DE602005003957T2 (de) | Mit doppelextrusionsverfahren hergestelltes augenimplantat | |
| RU2664686C2 (ru) | Способ лечения повышенного внутриглазного давления с помощью внутриглазной системы доставки лекарственного средства с замедленным высвобождением | |
| DE69635734T2 (de) | Verbesserte formulierung zur gesteuerten arzneistofffreisetzung durch kombination hydrophiler und hydrophober stoffe | |
| KR101430760B1 (ko) | 후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법 | |
| Hashizoe et al. | Scleral plug of biodegradable polymers for controlled drug release in the vitreous | |
| US5766619A (en) | Pharmaceutical dosage form for ocular administration and preparation process | |
| RU2749426C2 (ru) | Неинвазивная методика доставки лекарственного средства с помощью глазного вкладыша | |
| JPH10507743A (ja) | 薬剤投与のための方法と手段 | |
| AU2005294382A1 (en) | Ocular delivery of polymeric delivery formulations | |
| WO1995003009A1 (fr) | Methode de traitement de la degenerescence maculaire | |
| Einmahl et al. | A viscous bioerodible poly (ortho ester) as a new biomaterial for intraocular application | |
| EA032183B1 (ru) | Устройство для внутриглазной доставки лекарственного средства, способ его получения и способы его применения | |
| JPH02702A (ja) | 生物分解性眼移植物 | |
| US5308624A (en) | Ophthalmic product | |
| JPH054924A (ja) | 徐放製剤 | |
| CN109077993B (zh) | 一种泪小管缓释水凝胶植入剂及其制备方法 | |
| JP6720447B2 (ja) | 酸感受性薬剤の送達のための薬剤送達系 | |
| WO2014066658A1 (fr) | Systèmes d'administration de médicament à libération prolongée contenant du kétorolac | |
| CN114533648B (zh) | 一种阿西替尼眼内植入剂 | |
| Hashizoe et al. | Implantable biodegradable polymeric device in the treatment of experimental proliferative vitreoretinopathy | |
| JP3603129B2 (ja) | 糖尿病性角膜症の治療剤 | |
| CN113797162B (zh) | 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂 | |
| AU2002301863B2 (en) | Method for decreasing capillary permeability in the retina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE |
|
| 17P | Request for examination filed |
Effective date: 19920807 |
|
| 17Q | First examination report despatched |
Effective date: 19930809 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 19940222 |